B-cell hematologic malignancies
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Meet the following conditions of CD19 positive patients with acute lymphocytic leukemia or lymphoma: 1. History of the treatment: 1) Recurrence of B-cell lymphoma patients with imaging (CT/MRI/PET-CT) detection and pathological diagnosis, or recurrence including bone marrow morphology relapse and the MRD recurrence of acute B-cell leukemia patients, after chemotherapy or stem cell transplantation; 2) Can't get complete remission after more than twice repeated chemotherapy of B-cell lymphoma or acute B-cell leukemia patients; 3) Can't get remission after one or twice chemotherapy, also not suitable for chemotherapy of acute B-cell leukemia patients. 2. ECOG score=2; 3. To be aged 1 to 70 years; 4. More than a month lifetime from the consent signing date.
Exclusion criteria
Exclusion criteria: 1. Serious cardiac insufficiency, left ventricular ejection fraction<50; 2. Has a history of severe pulmonary function damaging; 3. Merging other malignant tumor; 4. Merging uncontrolled infection; 5. Merging the metabolic diseases (Except for diabetes); 6. Merging severe autoimmune diseases or immunodeficiency disease; 7. patients with active hepatitis B or hepatitis C; 8. patients with HIV infection; 9. Has a history of serious allergies on Biological products (including antibiotics); 10. Happened in 3 ~ 4 acute GvHD after allogeneic hematopoietic stem cell transplantation on recurring patients 11. Pregnancy or lactation women; 12. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate;overall response rate;Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Countries
China
Contacts
The Second Hospital of Hebei Medical University